ONWARD Medical has announced that it has completed enrolment in the LIFT Home study, which is designed to evaluate the safety and performance of ARCEX Therapy when used in the home.
ONWARD’s ARCEX Therapy is externally delivered programmed stimulation of the spinal cord which is designed to restore strength and function in people with spinal cord injury (SCI) and other movement related challenges.
The study enrolled 17 participants at five research centres in the United States: Craig Hospital (Denver), Shepherd Center (Atlanta), Spaulding Research Institute (Boston), University of Minnesota (Minneapolis) and University of Washington (Seattle). Subjects were followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit.
Candy Tefertiller, executive director of research and evaluation at Craig Hospital and primary investigator of the study, said: “The LIFT Home study is an important next step in understanding the potential benefits people with spinal cord injury may derive from continued access to ARC Therapy outside the clinic. We are pleased enrolment is now complete and we look forward to completing follow-up activities.”
The LIFT Home study is a successor to ONWARD’s Up-LIFT study, a pivotal trial that completed enrolment of 65 participants in December 2021, with participating research centres in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate if ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting. The LIFT Home study seeks to evaluate the potential impact of ARCEX Therapy when used in the home setting.
Dave Marver, CEO of ONWARD, commented: “We are grateful to collaborate with these outstanding researchers to investigate new potential benefits and care settings for our ARCEX Therapy. This is another step in our journey to help people with spinal cord injury regain function and independence.”